# rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study

> **NCT03829449** · PHASE3 · TERMINATED · sponsor: **AKARI Therapeutics** · enrollment: 15 (actual)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria

## Interventions

- **DRUG:** rVA576

## Key facts

- **NCT ID:** NCT03829449
- **Lead sponsor:** AKARI Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-13
- **Primary completion:** 2020-08-29
- **Final completion:** 2020-08-29
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** The early termination of this study is a business decision, Akari have made the decision to close their global Phase III PNH program. The decision was not related to any efficacy, safety or clinical concerns regarding Coversin/rVA576.
- **Last updated:** 2025-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03829449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03829449, "rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03829449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*